{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:06:45Z","timestamp":1762459605482,"version":"3.37.3"},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T00:00:00Z","timestamp":1526515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The phase 3 <jats:styled-content style=\"fixed-case\">PANORAMA<\/jats:styled-content>\u20101 trial led to regulatory approvals of panobinostat (<jats:styled-content style=\"fixed-case\">PAN<\/jats:styled-content>) in combination with bortezomib (<jats:styled-content style=\"fixed-case\">BTZ<\/jats:styled-content>) and dexamethasone (<jats:styled-content style=\"fixed-case\">DEX<\/jats:styled-content>) for the treatment of multiple myeloma after \u22652 prior regimens, including <jats:styled-content style=\"fixed-case\">BTZ<\/jats:styled-content> and an immunomodulatory drug. Patient\u2010reported outcomes (<jats:styled-content style=\"fixed-case\">PRO<\/jats:styled-content>s) were assessed in <jats:styled-content style=\"fixed-case\">PANORAMA<\/jats:styled-content>\u20101, with data available for 73 patients in the <jats:styled-content style=\"fixed-case\">PAN<\/jats:styled-content>\u00a0+\u00a0<jats:styled-content style=\"fixed-case\">BTZ<\/jats:styled-content>\u00a0+\u00a0<jats:styled-content style=\"fixed-case\">DEX<\/jats:styled-content> arm and 74 patients in the placebo (<jats:styled-content style=\"fixed-case\">PBO<\/jats:styled-content>)\u00a0+\u00a0<jats:styled-content style=\"fixed-case\">BTZ<\/jats:styled-content>\u00a0+\u00a0<jats:styled-content style=\"fixed-case\">DEX<\/jats:styled-content> arm. Per the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire\u2010Core 30 (<jats:styled-content style=\"fixed-case\">EORTC QLQ<\/jats:styled-content>\u2010C30), global health status\/quality of life (QoL) scores initially declined with <jats:styled-content style=\"fixed-case\">PAN<\/jats:styled-content>\u00a0+\u00a0<jats:styled-content style=\"fixed-case\">BTZ<\/jats:styled-content>\u00a0+\u00a0<jats:styled-content style=\"fixed-case\">DEX<\/jats:styled-content> during the first 24\u00a0weeks before approaching baseline scores and remaining steady during the next 24\u00a0weeks, with no difference between arms at Week 48. The <jats:styled-content style=\"fixed-case\">EORTC QLQ<\/jats:styled-content>\u2010Myeloma module (<jats:styled-content style=\"fixed-case\">EORTC QLQ<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">MY<\/jats:styled-content>20) demonstrated initial improvements and subsequent stabilization of disease symptom scores in both arms and initial worsening and subsequent improvement of side effects of treatment scores, with the initial worsening more pronounced and recovery less pronounced with <jats:styled-content style=\"fixed-case\">PAN<\/jats:styled-content>\u00a0+\u00a0<jats:styled-content style=\"fixed-case\">BTZ<\/jats:styled-content>\u00a0+\u00a0<jats:styled-content style=\"fixed-case\">DEX<\/jats:styled-content>. Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group\u2010Neurotoxicity scores remained relatively stable and similar between the arms. Overall, these <jats:styled-content style=\"fixed-case\">PRO<\/jats:styled-content> findings support the addition of <jats:styled-content style=\"fixed-case\">PAN<\/jats:styled-content> to the <jats:styled-content style=\"fixed-case\">BTZ<\/jats:styled-content>+<jats:styled-content style=\"fixed-case\">DEX<\/jats:styled-content> regimen as an efficacious treatment option, with limited symptomatology and impact on patients\u2019 QoL. The reported results are based on a descriptive analysis of the data. No formal statistical tests have been performed.<\/jats:p>","DOI":"10.1111\/bjh.15248","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T03:05:26Z","timestamp":1526612726000},"page":"628-636","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Patient\u2010reported outcomes of multiple myeloma patients treated with panobinostat after \u22652 lines of therapy based on the international phase 3, randomized, double\u2010blind, placebo\u2010controlled <scp>PANORAMA<\/scp>\u20101 trial"],"prefix":"10.1111","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-8865","authenticated-orcid":false,"given":"Paul G.","family":"Richardson","sequence":"first","affiliation":[{"name":"Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Schlossman","sequence":"additional","affiliation":[{"name":"Jerome Lipper Multiple Myeloma Center Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuja N.","family":"Roy","sequence":"additional","affiliation":[{"name":"Novartis East Hanover NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Panneerselvam","sequence":"additional","affiliation":[{"name":"Novartis East Hanover NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suddhasatta","family":"Acharyya","sequence":"additional","affiliation":[{"name":"Novartis East Hanover NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Sopala","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute Emory University School of Medicine Atlanta GA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,5,17]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22921"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.119735"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-294983"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28340"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2003.13603.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.04.022"},{"issue":"7","key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"vii143","DOI":"10.1093\/annonc\/mdq370","article-title":"Multiple myeloma","volume":"21","author":"Dimopoulos M.A.","year":"2010","journal-title":"Annals of Oncology"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00127-7"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7643-8948-2"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13243"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3322\/CA.57.5.301"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049909116646337"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07378.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01831.x"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2264-0"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2015-5380"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.63"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-665018"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70440-1"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.6706"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2518"},{"key":"e_1_2_9_24_1","article-title":"Phase I\/II trial of the efficacy and safety of combination therapy with lenalidomide\/bortezomib\/dexamethasone (RVD) and panobinostat in transplant\u2010eligible patients with newly diagnosed multiple myeloma","volume":"126","author":"Shah J.J.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.185"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01206.x"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-015-1925-7"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30375-8"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15248","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15248","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T21:51:00Z","timestamp":1695505860000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,17]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1111\/bjh.15248"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15248","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2018,5,17]]},"assertion":[{"value":"2017-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}